Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

If You Like Fuel Cell Energy, Bloom Energy Might Be The Safer Bet

By Will Ashworth, InvestorPlace Contributor

While FCEL stock is an interesting play, FuelCell Energy reported disappointing Q4 2019 results, making Bloom Energy the safer play.

7 Reasons to Own Taylor Morrison Stock

By Will Ashworth, InvestorPlace Contributor

Taylor Morrison recently got out of Chicago. Here are seven reasons why you should still own Taylor Morrison stock. 

Beyond Meat Stock Could Be in Trouble Due to Rising Legal Concern

By Will Ashworth, InvestorPlace Contributor

Beyond Meat faces mounting legal pressures that could provide owners of Beyond Meat stock with indigestion moving forward.

The Odds of Freeport-McMoRan Stock Hitting $60 Again Are Good

By Will Ashworth, InvestorPlace Contributor

The coronavirus could affect Freeport-McMoRan in the short term, but the long-term demand for copper should be good for FCX stock.

What Inovio Pharma’s $100 Million Addition to Its Shelf Offering Means for INO Stock 

By Will Ashworth, InvestorPlace Contributor

Like many pharmaceutical companies, Inovio loses a lot of money. As of September 30, 2019, it had an accumulated deficit of $702 million, which means it’s lost $702 million over its history. 

Load More